Bioheart has planned to establish two centres of excellence in the region, to provide its cell therapy procedures to patients of congestive heart failure (CHF) and peripheral arterial disease (PAD).
'We feel that the Middle East region
Mideast-backed US-based Bioheart will conduct a ground-breaking clinical trial on patients with congestive heart failure with a genetically-modified process in Jordan Hospital, said a top executive.
Bioheart, which is backed by the Middle
US-based Bioheart has announced a medical breakthrough in cardiovascular therapy by using stem cells of fat tissues of patient’s own body.
Regeneration of a damaged heart is possible through stem cells derived from a patient’s own fat tis
The Philadelphia Biological and Medical Technology Product Development Centre in Amman, Jordan has made a major medical breakthrough in the treatment of potentially life-threatening, heart-related aliments.
According to Peggy Farley, manag